VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Written informed consent                           │ Written informed consent                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has undergone first time isolated CABG due to an   │ Has undergone first time isolated CABG due to an   │     100 │
│ episode of acute coronary syndrome (STEMI, NSTEMI, │ episode of acute coronary syndrome (STEMI, NSTEMI, │         │
│ unstable angina) within 6 weeks before surgery     │ unstable angina) within 6 weeks before surgery     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previously enrolled in this study (i.e. patient    │ Previously enrolled in this study (i.e. patient    │     100 │
│ now at repeat encounter)                           │ now at repeat encounter)                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant surgical procedure other than CABG     │ Concomitant surgical procedure other than CABG     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anticoagulant treatment after the operation (e.g.  │ Anticoagulant treatment after the operation (e.g.  │     100 │
│ warfarin, direct thrombin inhibitors (dabigatran), │ warfarin, direct thrombin inhibitors (dabigatran), │         │
│ FXa inhibitors (rivaroxaban, apixaban, heparin,    │ FXa inhibitors (rivaroxaban, apixaban, heparin,    │         │
│ low-molecular weight heparin, fondaparinux)        │ low-molecular weight heparin, fondaparinux)        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Discharge from the operating hospital to an ICU at │ Discharge from the operating hospital to an ICU at │     100 │
│ another hospital                                   │ another hospital                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy or lactation                             │ Pregnancy or lactation                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known intolerance or contraindication to           │ Known intolerance or contraindication to           │     100 │
│ ticagrelor or ASA                                  │ ticagrelor or ASA                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any disorder that may interfere with drug          │ Any disorder that may interfere with drug          │     100 │
│ absorption                                         │ absorption                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known chronic liver disease, renal disease         │ Known chronic liver disease, renal disease         │     100 │
│ requiring dialysis or bleeding disorder            │ requiring dialysis or bleeding disorder            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Atrioventricular block II and III in patients      │ Atrioventricular block II and III in patients      │     100 │
│ without pacemaker                                  │ without pacemaker                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any other indication for dual antiplatelet         │ Any other indication for dual antiplatelet         │     100 │
│ therapy, i.e. recent stent implantation            │ therapy, i.e. recent stent implantation            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Debilitating stroke within 90 days before          │ Debilitating stroke within 90 days before          │     100 │
│ inclusion                                          │ inclusion                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous intracranial bleeding                     │ Previous intracranial bleeding                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with immunosuppressants (e.g.            │ Treatment with immunosuppressants (e.g.            │     100 │
│ cyclosporine and tacrolimus)                       │ cyclosporine and tacrolimus)                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with strong CYP3A4-inhibitors (e.g.      │ Treatment with strong CYP3A4-inhibitors (e.g.      │     100 │
│ ketoconazole, clarithromycin, nefazodone,          │ ketoconazole, clarithromycin, nefazodone,          │         │
│ ritonavir or atazanavir)                           │ ritonavir or atazanavir)                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any condition that in the opinion of the           │ Any condition that in the opinion of the           │     100 │
│ investigator may interfere with adherence to trial │ investigator may interfere with adherence to trial │         │
│ protocol                                           │ protocol                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age ≥18 years                                      │ Age =18 years                                      │      92 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any condition other than coronary artery disease   │ Any condition other than coronary artery disease   │      99 │
│ with a life expectancy \<12 months                 │ with a life expectancy <12 months                  │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                               │ CHIA Criteria                                      │   Score │
╞═════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years               │ Age =18 years                                      │      43 │
├─────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in any other clinical trial       │ Any condition that in the opinion of the           │      47 │
│ evaluating investigational products at the time │ investigator may interfere with adherence to trial │         │
│ for enrollment in this study                    │ protocol                                           │         │
╘═════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 95
Average Levenshtein Ratio of individual lines: 94.33333333333333
OverAll Ratio: 94.66666666666666
